Last reviewed · How we verify
Amyloid polyneuropathy type I
Approved treatments
- Vyndaqel · Foldrx Pharms
Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation. - Vyndaqel · Foldrx Pharms
Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils. - Vyndaqel · Foldrx Pharms
Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils. - Vyndaqel · Foldrx Pharms
Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils.
Clinical guidelines
- FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. - FDA label — any
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Amyloid polyneuropathy type I patent landscape — cliff calendar, originator estates, attackable patents
- Amyloid polyneuropathy type I treatment landscape brief
- Amyloid polyneuropathy type I treatment updates RSS
Frequently asked questions about Amyloid polyneuropathy type I
What drugs treat Amyloid polyneuropathy type I?
Tracked treatments include Vyndaqel.
What is the treatment for Amyloid polyneuropathy type I?
Standard treatment for Amyloid polyneuropathy type I includes Vyndaqel. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Amyloid polyneuropathy type I?
FDA label publishes guidelines for Amyloid polyneuropathy type I. 8 guideline references tracked.
Related
- Treatment landscape: Amyloid polyneuropathy type I patent cliff · Amyloid polyneuropathy type I CI report
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- Treatment: Vyndaqel · Foldrx Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing